P27A Malaria Vaccine - MALARIA VACCINE - Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel

Further research and optimisation of new malaria vaccines and technologies is ongoing at Swiss TPH. This includes testing of new candidates in Africa such as P27a that was brought in one go from a Phase Ia clinical trial in Switzerland to a Phase Ib in Tanzania, paving the way for an accelerated pathway for clinical development and early involvement of African scientists into the overall process. Detailed immunological analyses performed on site in Bagamoyo revealed that the novel adjuvant GLA-SE induces significant cellular immune responses specific for P27a in malaria pre-exposed volunteers.